Glioblastoma-associated surface antigens (GAA)

U87 glioblastoma-associated surface antigens refer to the heterogeneous collection of proteins expressed on the plasma membrane of the U-87 MG cell line and primary glioblastoma multiforme (GBM) tumors. These antigens, which include well-characterized molecules such as EGFRvIII, IL-13Rα2, HER2, and B7-H3, serve as critical targets for the development of precision immunotherapies, including chimeric antigen receptor (CAR) T-cells and therapeutic vaccines. In the context of glioblastoma, these surface molecules often drive oncogenic signaling pathways, promote tumor cell invasion, and facilitate immune evasion within the brain's microenvironment. Because glioblastoma is characterized by significant intratumoral heterogeneity, many therapeutic strategies aim to target multiple antigens simultaneously to prevent antigen escape and disease recurrence. While the term 'U87 glioblastoma-associated surface antigens' describes a group of targets rather than a single molecular entity, it represents the collective 'surfaceome' used in preclinical research to identify and validate novel therapeutic vulnerabilities in malignant gliomas. Clinical development in this area must address challenges such as the blood-brain barrier and the potential for on-target off-tumor toxicity in healthy neural tissues.

Other names

U87 glioblastoma-associated surface antigensU87-MG surface antigensGlioma-associated antigensGBM surface antigensTumor-associated antigens (TAA) in glioblastoma

Targeted immunotherapy (including CAR T-cells, vaccines, and antibody-drug conjugates) directed against specific surface-expressed proteins to induce tumor cell lysis or immune-mediated destruction.